Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
NEW YORK - Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company with a market capitalization of $12.55 million and strong recent momentum showing a 9.66% gain last week, today announced significant preclinical results for HT-KIT, its antisense oligonucleotide therapy targeting rare and treatment-resistant cancers. According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt. The preclinical studies demonstrated over an 80% reduction in KIT expression and substantial tumor growth inhibition in gastrointestinal stromal tumors (GIST) and systemic mastocytosis models, with no observed off-target toxicity, indicating a favorable safety profile.
HT-KIT, designed to target and silence aberrant KIT gene expression, has shown potential in overcoming resistance to current treatments, which often lead to drug resistance or systemic side effects. The therapy works by binding to mutant KIT mRNA transcripts, preventing the production of the KIT protein, a known driver of tumor growth in certain cancers.
Robb Knie, CEO of Hoth Therapeutics, expressed optimism about HT-KIT’s role in precision oncology, particularly for patients who have exhausted traditional therapies. The company is preparing to submit an Investigational New Drug (IND) application to the FDA in early 2026, with Phase 1 human trials expected to follow soon after. Analysts share this optimism, with price targets ranging from $4 to $5, suggesting significant upside potential from current levels.
Hoth Therapeutics focuses on developing treatments for unmet medical needs, emphasizing early-stage research and development. The company collaborates with scientists and clinicians to advance promising therapeutics from pre-clinical to clinical testing stages.
The information provided is based on a press release statement from Hoth Therapeutics, Inc. Investors are reminded that forward-looking statements involve risks and uncertainties, and actual events could differ materially from those indicated due to various factors, including market conditions and regulatory approval processes. For comprehensive financial analysis and additional insights, including 8 more exclusive ProTips, visit InvestingPro to make more informed investment decisions.
In other recent news, Hoth Therapeutics has made significant strides in its research and development efforts. The company announced promising interim results from its Phase 2a clinical trial for HT-001, a treatment aimed at alleviating pruritus associated with skin toxicities from cancer treatments. Patients in the trial reported a 50% reduction in pruritus severity, with no serious adverse events, highlighting the potential of HT-001 to improve patient quality of life. Additionally, Hoth Therapeutics reported encouraging preclinical results for its Alzheimer’s drug candidate, HT-ALZ, which demonstrated cognitive improvements and reduced neuroinflammation in disease models. The company also secured a new patent in Japan for its RNA cancer therapy targeting the KIT gene, reinforcing its intellectual property in the RNA therapeutics space. Furthermore, Hoth Therapeutics has filed amended claims to enhance the patent protection for its lead antisense oligonucleotide drug candidate, HT-KIT, and initiated a toxicity study to evaluate its safety. These developments underscore Hoth Therapeutics’ ongoing efforts to advance its pipeline of innovative therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.